The efflux pump inhibitor tetrandrine exhibits synergism with fluconazole or voriconazole against Candida parapsilosis
- 17 Downloads
In the last two decades, with the wide use of azoles, antifungal resistance among Candida parapsilosis has considered a matter of concern worldwide. The aim of this study is to evaluate the antifungal potentials of tetrandrine (TET) alone and in combination with fluconazole (FLC)/voriconazole (VRC) against C. parapsilosis. Susceptibility tests were performed by microdilution method, checkerboard assay, time-kill test, spot assay. Subsequently, rhodamine 6G efflux test and the expressions of transporter related genes, namely CDR1 and MDR1 for C. parapsilosis were analyzed by qRT-PCR. The susceptibility test showed that TET presented strong synergism with FLC and VRC with fractional inhibitory concentration index (FICI) in a range of 0.094–0.562. The susceptibility results were also confirmed by spot assay and time-kill studies. With TET treatment, a vast quantity of rhodamine 6G could not be pumped out from the cells as considerably intracellular red fluorescence was accumulated. Meanwhile, the expressions of efflux-associated genes presented varying degrees of inhibition. These results indicated that TET was a decent antifungal synergist to promote the antifungal efficacy of FLC/VRC, and the underlying antifungal mechanism might be associated with the inhibition of efflux pump and the elevation of intracellular drug content.
KeywordsTetrandrine (TET) Fluconazole (FLC) Voriconazole (VRC) Candida parapsilosis Synergism
All the authors conceived the study, participated in its design and coordination and collected and managed the data. YZ drafted the manuscript, and all authors contributed substantially to its revision. All the authors read and approved the final manuscript.
This work was supported by the National Nature Science Foundation of China (Grant No. 81471995).
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
- 1.Pais P, Costa C, Pires C, Shimizu K, Chibana H, Teixeira MC (2016) Membrane proteome-wide response to the antifungal drug clotrimazole in Candida glabrata: role of the transcription factor CgPdr1 and the drug: H+ antiporters CgTpo1_1 and CgTpo1_2. Mol Cell Proteomics 15:57–72. https://doi.org/10.1074/mcp.M114.045344 CrossRefGoogle Scholar
- 2.Marcos-Zambrano LJ, Escribano P, Sanchez C, Munoz P, Bouza E, Guinea J (2014) Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother 58:4565–4572. https://doi.org/10.1128/AAC.02670-14 CrossRefGoogle Scholar
- 4.Souza AC, Fuchs BB, Pinhati HM, Siqueira RA, Hagen F, Meis JF, Mylonakis E, Colombo AL (2015) Candida parapsilosis resistance to fluconazole: molecular mechanisms and in vivo impact in infected Galleria mellonella larvae. Antimicrob Agents Chemother 59:6581–6587. https://doi.org/10.1128/AAC.01177-15 CrossRefGoogle Scholar
- 5.Berkow EL, Manigaba K, Parker JE, Barker KS, Kelly SL, Rogers PD (2015) Multidrug transporters and alterations in sterol biosynthesis contribute to azole antifungal resistance in Candida parapsilosis. Antimicrob Agents Chemother 59:5942–5950. https://doi.org/10.1128/AAC.01358-15 CrossRefGoogle Scholar
- 6.Canton E, Peman J, Quindos G, Eraso E, Miranda-Zapico I, Alvarez M, Merino P, Campos-Herrero I, Marco F, de la Pedrosa EG, Yague G, Guna R, Rubio C, Miranda C, Pazos C, Velasco D, Group FS (2011) Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother 55:5590–5596. https://doi.org/10.1128/aac.00466-11 CrossRefGoogle Scholar
- 11.Li SX, Song YJ, Zhang LL, Shi JP, Ma ZL, Guo H, Dong HY, Li YM, Zhang H (2015) An in vitro and in vivo study on the synergistic effect and mechanism of itraconazole or voriconazole alone and in combination with tetrandrine against Aspergillus fumigatus. J Med Microbiol 64:1008–1020. https://doi.org/10.1099/jmm.0.000120 CrossRefGoogle Scholar
- 12.Clinical and Laboratory Standard Institute (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved Standard-Third Edition. CLSI document M27-A3. 2008. Clinical and Laboratory Standards Institute, Wayne, PAGoogle Scholar
- 13.Clinical and Laboratory Standard Institute (2012) Reference method for broth dilution antifungal susceptibility testing of yeasts; Fourth Informational Supplement M27-S4. Clinical and Laboratory Standards Institute, Wayne, PAGoogle Scholar
- 15.Shao J, Shi G, Wang T, Wu D, Wang C (2016) Antiproliferation of berberine in combination with fluconazole from the perspectives of reactive oxygen species, ergosterol and drug efflux in a fluconazole-resistant Candida tropicalis isolate. Front Microbiol 7:1516. https://doi.org/10.3389/fmicb.2016.01516 CrossRefGoogle Scholar
- 16.Wang T, Shao J, Da W, Li Q, Shi G, Wu D, Wang C (2018) Strong synergism of palmatine and fluconazole/itraconazole against planktonic and biofilm cells of Candida species and efflux-associated antifungal mechanism. Front Microbiol 9:2892. https://doi.org/10.3389/fmicb.2018.02892 CrossRefGoogle Scholar